Australia, Aug. 26 -- Amgen Inc., owns the trademark (2662128) for 'BYSTEAPIX' till June 12, 2036.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations.] and 5 [All items in this class are claimed in the convention application.]
Type of Mark: Word
Date of Acceptance: June 18
Registration Advertised: Aug. 25
For further details contact Spruson & Ferguson.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2662128.
Disclaimer: Curated by HT Syndication.
